Page last updated: 2024-08-21

pyrazines and selexipag

pyrazines has been researched along with selexipag in 125 studies

Research

Studies (125)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (2.40)29.6817
2010's81 (64.80)24.3611
2020's41 (32.80)2.80

Authors

AuthorsStudies
Asaki, T; Hamamoto, T; Hashino, A; Kuwabara, K; Kuwano, K; Okubo, K; Yamada, T1
Asaki, T; Nakamura, A; Yamada, T1
Hashino, A; Kosugi, K; Kuwabara, K; Kuwano, K; Noda, K1
Clozel, M; Ernst, R; Hess, P; Morrison, K; Studer, R1
Bonderman, D; Degano, B; Delcroix, M; Efficace, M; Galiè, N; Giorgino, R; Hoeper, MM; Karlócai, K; Kurzyna, M; Lang, IM; Simonneau, G; Torbicki, A1
Clozel, M; Ernst, R; Haag, F; Kauser, K; Morrison, K; Studer, R1
Kovacs, G; Olschewski, H1
Morrell, N; Sitbon, O1
Clapp, LH; Ledwozyw, A; Orie, NN; Whittle, BJ; Williams, DJ1
Lang, IM; Skoro-Sajer, N1
Bruderer, S; Dingemanse, J; Hurst, N; Kaufmann, P1
Bruderer, S; Darpo, B; Dingemanse, J; Hoch, M; Kaufmann, P; Remenova, T; Stoltz, R; Zhou, M1
Bruderer, S; Dingemanse, J; Kaufmann, P; Mant, T; Mukai, H; Okubo, K; Yamada, T1
Äänismaa, P; Bruderer, S; Dingemanse, J; Halabi, A; Kaufmann, P; Niglis, S; Segrestaa, J1
Baldoni, D; Bruderer, S; Dingemanse, J; Muhsen, N1
Asaki, T; Clozel, M; Gatfield, J; Hamamoto, T; Kuwano, K; Morrison, K1
Sharma, K1
Adzerikho, I; Channick, R; Chin, KM; Di Scala, L; Frey, A; Gaine, S; Galiè, N; Ghofrani, HA; Hoeper, MM; Lang, IM; Liu, J; McLaughlin, VV; Moiseeva, O; Preiss, R; Rubin, LJ; Simonneau, G; Sitbon, O; Tapson, V; Zeng, X1
Amar, D; Boucly, A; Chaumais, MC; Humbert, M; Jaïs, X; Montani, D; O'Connell, C; Savale, L; Simonneau, G; Sitbon, O1
Scott, LJ1
Advani, A; Advani, SL; Azizi, PM; Batchu, SN; Bowskill, BB; Brijmohan, AS; Lee, WL; Liu, Y; Majumder, S; Thai, K; White, KE1
Cruz, HG; Dingemanse, J; Halabi, A; Kaufmann, P; Krause, A; Ulč, I1
Bruderer, S; Dingemanse, J; Mant, T; Mukai, H; Okubo, K1
Channick, RN; Tamura, Y1
Gall, H; Ghofrani, HA; Grimminger, F; Grimminger, J; Richter, MJ1
Horn, EM; Krishnan, U1
Adams, H; Prior, DL; Williams, TJ1
Ball, S; Bandyopadhyay, D; Das, A; Ghosh, RK; Gupta, A; Mondal, S; Saha, D1
Farber, HW; Moll, M; Sardana, M1
Astruc, B; Dingemanse, J; Hurst, N; Kaufmann, P1
Chin, KM; Hardin, EA1
Allanore, Y; Bruni, C; Distler, O; Gabrielli, A; Iannone, F; Matucci-Cerinic, M; Praino, E1
Kaluski, E; Mishra, A; Singh, M1
Fuchikami, C; Homan, J; Kosugi, K; Kuramoto, K; Kuwano, K; Murakami, K; Oka, M; Tajima, K1
Burness, CB; Duggan, ST; Keam, SJ1
Gnerre, C; Ichikawa, T; Nonaka, K; Treiber, A; Yamada, T1
Del Pozo, R; Escribano-Subias, P; Hernandez Gonzalez, I1
Anzai, T; Fukuda, K; Hashimoto, A; Hatano, M; Ikeda, S; Inoue, T; Ito, H; Kajinami, K; Kihara, Y; Kinoshita, H; Kuwahara, K; Murohara, T; Nakayama, T; Okazaki, O; Sakai, S; Sasayama, S; Satoh, T; Tahara, N; Takeda, Y; Takeishi, Y; Tanabe, N; Taniguchi, M; Watanabe, H; Yamamoto, T; Yamauchi-Takihara, K; Yoshioka, K1
Clozel, M; Gatfield, J; Gnerre, C; Hess, P; Iglarz, M; Menyhart, K; Monnier, L; Morrison, K; Nayler, O; Wanner, D1
Baker, WL; Darsaklis, K; Salerno, EL; Singhvi, A1
Bruderer, S; Dingemanse, J; Hurst, N; Remenova, T1
Bates, RE; Frantz, RP; Thurber, KM; Williams, BM1
Honorato Pérez, J1
Kido, K; Macaulay, TE; Noel, ZR1
Bruderer, S; Dingemanse, J; Hurst, N; Krause, A; Lott, D; Machacek, M1
Boehler, M; Bruderer, S; Dingemanse, J; Donazzolo, Y; Juif, PE1
Boehler, M; Bruderer, S; Dingemanse, J; Ulč, I1
Alejos, J; Drogalis-Kim, DE; Gallotti, R; Satou, G1
Boehler, M; Bruderer, S; Dingemanse, J; Halabi, A; Petersen-Sylla, M; Remeňová, T1
Äänismaa, P; de Kanter, R; Delahaye, S; Gnerre, C; Ichikawa, T; Pfeifer, T; Seeland, S; Segrestaa, J; Treiber, A; Yamada, T1
Hansmann, G; Koestenberger, M1
Channick, R; Chin, K; Coghlan, G; Di Scala, L; Gaine, S; Galiè, N; Ghofrani, HA; Hoeper, MM; Lang, IM; McLaughlin, V; Preiss, R; Rubin, LJ; Simonneau, G; Sitbon, O; Tapson, VF1
Seibold, JR; Wigley, FM1
Grimm, D; Infanger, M; Kruger, M; Nassef, MZ; Simonsen, U; Sorensen, LM; Wehland, M1
Dutt, M; Feldman, J; Habib, N; Radosevich, J1
Hussar, DA1
El Yafawi, R; Wirth, JA1
Furukawa, A; Goto, M; Iwahori, H; Kawamura, A; Ohashi, N; Okabe, T; Tamura, Y1
Channick, RN; Chin, K; Di Scala, L; Farber, HW; Gaine, S; Galiè, N; Ghofrani, HA; Hoeper, MM; Lang, IM; McLaughlin, VV; Preiss, R; Preston, IR; Rubin, LJ; Simonneau, G; Sitbon, O; Tapson, VF1
Denton, CP; Frenoux, JM; Frey, A; Hachulla, É; Herrick, AL; Le Brun, FO; Riemekasten, G; Schwarting, A1
Channick, R; Chin, K; Coghlan, JG; Di Scala, L; Gaine, S; Galiè, N; Ghofrani, HA; Hoeper, MM; Lang, IM; McLaughlin, V; Preiss, R; Rubin, LJ; Simonneau, G; Sitbon, O; Tapson, VF1
Gnerre, C; Ichikawa, T; Nonaka, K; Seeland, S; Segrestaa, J; Treiber, A; Yamada, T1
Denton, CP; Herrick, AL1
Domsic, RT; Pauling, JD; Saketkoo, LA1
Greene, RA1
Noel, ZR1
Clozel, M; Ernst, R; Haag, F; Iglarz, M; Morrison, K1
Brizzolara, R; Corallo, C; Cutolo, M; Giordano, N; Montagna, P; Paolino, S; Parodi, A; Pizzorni, C; Ruaro, B; Scabini, S; Smith, V; Soldano, S; Stratta, E; Sulli, A; Tavilla, PP; Trombetta, AC1
Boerema-de Munck, A; Burgisser, PE; Buscop-van Kempen, MJ; Dzyubachyk, O; Kool, HM; Mous, DS; Nagata, K; Rottier, RJ; Tibboel, D; van Rosmalen, J; Wijnen, RMH1
Ecker-Schlipf, B1
Akerström, F; Berenguel Senén, A; Escribano Subías, P; Lázaro Salvador, M; Martinez Mateo, V; Rodriguez Padial, L1
Ichikawa, T; Imai, S; Nonaka, K; Sugiyama, C; Yamada, T1
Fanous, SM; Janmohamed, M1
Benza, RL; Chin, KM; Eggert, M; Farber, HW; Fisher, M; Fortin, TA; Fritz, JS; Frost, A; Janmohamed, M; Kim, NH; McConnell, JW; McEvoy, C; McLaughlin, V; Miller, CE; Pfister, T; Poch, D; Shiraga, Y1
Ais, A; Beaudet, A; Gil, A; Jiménez, A1
Beghetti, M; Channick, RN; Chin, KM; Di Scala, L; Gaine, S; Galiè, N; Ghofrani, HA; Hoeper, MM; Lang, IM; McLaughlin, VV; Preiss, R; Rubin, LJ; Simonneau, G; Sitbon, O; Tapson, VF1
Airhart, S; Badie, N; Benza, R; Raina, A; Verlinden, N1
Escribano Subías, P; Lázaro Salvador, M; Rodriguez Padial, L1
Berlier, C; Lichtblau, M; Saxer, S; Schwarz, EI; Ulrich, S1
Channick, R; Chin, KM; Di Scala, L; Gaine, S; Galiè, N; Ghofrani, HA; Hoeper, MM; Lang, IM; McLaughlin, VV; Preiss, R; Rubin, LJ; Simonneau, G; Sitbon, O; Tapson, VF1
Bock, MJ; Koo, R; Lo, J1
Braverman, LE; Farber, HW; Menon, AA; Sahay, S1
Jin, Q; Liu, Z; Luo, Q; Xiong, C; Yan, L; Yu, X; Zhang, Y; Zhao, Q; Zhao, Z1
Dahhan, T; Doerfler, S; Fortin, T; Kennedy, K; Parikh, KS; Rajagopal, S; Shelburne, N; Whitson, J1
Benet, J; Bouvaist, H; Degano, B; Guillien, A; Picard, F; Piliero, N; Pison, C; Sitbon, O; Soumagne, T; Yanaka, K1
Bialesova, L; Bouchard, A; Kinsella, BT; Mulvaney, EP; Reid, HM; Salvail, D1
Lachant, DJ; White, RJ1
Bukova, M; Chouvarine, P; Hansmann, G; Koestenberger, M; Meinel, K; Wåhlander, H1
Goncharova, NS; Karelkina, EV; Moiseeva, OM; Simakova, MA1
Axelsen, LN; Bruderer, S; Perez Ruixo, JJ; Poggesi, I; Rasschaert, F1
Chan, KC; Das, BB; Jadotte, MM1
Burgos-Blasco, P; Diaz-Guimaraens, B; Dominguez-Santas, M; Ortega-Quijano, D; Saceda-Corralo, D; Suarez-Valle, A1
DeChristopher, A; Fann, J; Feldman, J; Irandost, M; Radosevich, JJ1
Amin, EK; Austin, ED; Colglazier, E; Fineman, JR; Hemnes, AR; Leary, PJ; Nawaytou, H; Parker, C; Teitel, D1
Chen, J; Shi, L; Xie, S; Xu, RA; Ye, X1
Burki, TK1
Boutou, A; Panagiotidou, E; Pitsiou, G1
Adachi, S; Kondo, T; Nakano, Y1
Benza, RL; Raina, A; Verlinden, NJ; Walter, C1
Hakamata, A; Inui, N; Kamiya, C; Katayama, N; Namiki, N; Odagiri, K; Tanaka, S; Tatsumi, K; Uchida, S; Watanabe, H1
Fuchikami, C; Honda, Y; Kosugi, K; Kuramoto, K; Kuwano, K; Numakura, Y1
Bernardo Reyes, AW; Kim, HJ; Kim, S; Lee, HJ; Lee, JH; Min, W; Ngoc Huy, TX; Vu, SH1
Beghetti, M; Genecand, L; Lador, F; Wacker, J1
Chakinala, MM; Chin, KM; Farber, HW; Hemnes, AR; Highland, KB; Kim, NH; McLaughlin, V; Narayan, V; Zhao, C1
Axelsen, LN; Chin, KM; Ewert, R; Gall, H; Hsu Schmitz, SF; Klose, H; Parambil, J; Poch, D; Preston, IR; Seyfarth, HJ; Stein, C1
Apostolopoulou, SC; Demerouti, EA; Karyofyllis, P1
Channick, RN; Chin, KM; Gaine, S; Galiè, N; Ghofrani, HA; Hoeper, MM; Lang, I; McLaughlin, VV; Preiss, R; Rubin, LJ; Sauter, R; Simonneau, G; Sitbon, O; Tapson, V1
Lafuente-Romero, A; Rodriguez Ogando, A1
Amara Babu, NLA; Koganti, K; Palakeeti, B; Rao, KP; Srinivas, KSV1
Berkson, L; Chartrand, S; Langleben, D1
Chin, KM; Doelberg, M; Feldman, J; Galiè, N; Gibbs, JSR; Grünig, E; Hoeper, MM; Martin, N; Mathai, SC; McLaughlin, VV; Perchenet, L; Poch, D; Saggar, R; Simonneau, G; Sitbon, O1
Channick, R; Chin, KM; Coghlan, JG; Gaine, S; Galiè, N; Hoeper, MM; Hsu Schmitz, SF; Lang, IM; Lassen, C; McLaughlin, VV; Rubin, LJ; Sitbon, O; Tapson, VF1
Avdeev, SN; Nekludova, GV; Proshkina, AA; Tsareva, NA1
Channick, R; Chin, KM; Du Roure, C; Gaine, S; Galiè, N; Ghofrani, HA; Hoeper, MM; Jenner, B; Lang, IM; McLaughlin, VV; Rosenkranz, S; Rubin, LJ; Sitbon, O; Tapson, V1
Maeder, MT1
Abe, K; Ako, J; Ikeda, Y; Joho, S; Kinoshita, H; Maki, H; Matoba, S; Motoki, H; Ogo, T; Saeki, T; Sakao, S; Shimokawahara, H; Shiota, N; Sugano, T; Takama, N; Tanabe, N; Tanaka, S; Tatsumi, K; Tsujino, I; Yamamoto, C; Yoshioka, K1
Chen, M; Chen, R; Hong, C; Lai, Y; Liu, H; Lu, J; Wang, D; Zhang, Y; Zheng, Z; Zhong, Y1
Chen, YA; Fan, C; Gu, EM; Luo, SB; Xu, RA; Zhou, SC1
Akashi, K; Arinobu, Y; Ayano, M; Fukata, M; Higashioka, K; Horiuchi, T; Imabayashi, K; Kashiwado, Y; Kawano, S; Kimoto, Y; Mitoma, H; Niiro, H; Ono, N; Saiki, C; Yokoyama, T1
Chen, H; Li, C; Liang, Y; Qiu, Y; Shen, Y; Xu, M1
Ghofrani, HA1
Liang, L; Ma, G; Wang, D; Xu, L; Xu, X1
Chouvarine, P; Diedrich, N; Diekmann, F; Hansmann, G; Hasan, H; Koestenberger, M1
Blanco, I; Cruz Utrilla, A; Del Pozo, R; Escribano-Subías, P; López-Meseguer, M1

Reviews

26 review(s) available for pyrazines and selexipag

ArticleYear
Pathways in pulmonary arterial hypertension: the future is here.
    European respiratory review : an official journal of the European Respiratory Society, 2012, Dec-01, Volume: 21, Issue:126

    Topics: Acetamides; Animals; Antihypertensive Agents; Benzamides; Clinical Trials as Topic; Drugs, Investigational; Endothelin A Receptor Antagonists; Endothelin B Receptor Antagonists; Endothelin-1; Epoprostenol; Guanylate Cyclase; Humans; Hypertension, Pulmonary; Imatinib Mesylate; Lisuride; Nitric Oxide; Phosphodiesterase 5 Inhibitors; Piperazines; Protein Kinase Inhibitors; Pyrazines; Pyrazoles; Pyrimidines; Serotonin Antagonists; Sulfonamides

2012
Selexipag for the treatment of pulmonary arterial hypertension.
    Expert opinion on pharmacotherapy, 2014, Volume: 15, Issue:3

    Topics: Acetamides; Acetates; Administration, Oral; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Familial Primary Pulmonary Hypertension; Humans; Hypertension, Pulmonary; Prostaglandins I; Pyrazines; Receptors, Prostaglandin; Signal Transduction

2014
Comparative Safety and Tolerability of Prostacyclins in Pulmonary Hypertension.
    Drug safety, 2016, Volume: 39, Issue:4

    Topics: Acetamides; Epoprostenol; Humans; Hypertension, Pulmonary; Prostaglandins I; Pyrazines; Randomized Controlled Trials as Topic; Receptors, Prostaglandin

2016
Selexipag: First Global Approval.
    Drugs, 2016, Volume: 76, Issue:3

    Topics: Acetamides; Administration, Oral; Antihypertensive Agents; Clinical Trials as Topic; Drug Approval; Humans; Hypertension, Pulmonary; Pyrazines; Receptors, Prostaglandin

2016
New paradigm for pulmonary arterial hypertension treatment.
    Current opinion in pulmonary medicine, 2016, Volume: 22, Issue:5

    Topics: Acetamides; Antihypertensive Agents; Clinical Trials as Topic; Endothelin Receptor Antagonists; Humans; Hypertension, Pulmonary; Inositol 1,4,5-Trisphosphate Receptors; Phenylpropionates; Phosphodiesterase 5 Inhibitors; Pyrazines; Pyridazines; Pyrimidines; Randomized Controlled Trials as Topic; Sulfonamides

2016
Selexipag for the treatment of pulmonary arterial hypertension.
    Expert opinion on pharmacotherapy, 2016, Volume: 17, Issue:13

    Topics: Acetamides; Administration, Oral; Animals; Drug Approval; Epoprostenol; Humans; Hypertension, Pulmonary; Pyrazines

2016
A Contemporary Approach to Pulmonary Arterial Hypertension.
    Current atherosclerosis reports, 2016, Volume: 18, Issue:9

    Topics: Acetamides; Antihypertensive Agents; Endothelin Receptor Antagonists; Humans; Hypertension, Pulmonary; Pyrazines; Pyrimidines; Sulfonamides

2016
Update on pharmacotherapy for pulmonary hypertension.
    The Medical journal of Australia, 2016, Sep-19, Volume: 205, Issue:6

    Topics: Acetamides; Antihypertensive Agents; Australia; Drug Therapy, Combination; Humans; Hypertension, Pulmonary; Pyrazines; Pyrazoles; Pyrimidines; Sulfonamides; World Health Organization

2016
Selexipag in Pulmonary Arterial Hypertension: Most Updated Evidence From Recent Preclinical and Clinical Studies.
    Journal of clinical pharmacology, 2017, Volume: 57, Issue:5

    Topics: Acetamides; Animals; Antihypertensive Agents; Drug Interactions; Humans; Hypertension, Pulmonary; Pyrazines

2017
Pharmacokinetic drug evaluation of selexipag for the treatment of pulmonary arterial hypertension.
    Expert opinion on drug metabolism & toxicology, 2016, Volume: 12, Issue:12

    Topics: Acetamides; Administration, Oral; Animals; Antihypertensive Agents; Delayed-Action Preparations; Drug Evaluation, Preclinical; Humans; Hypertension, Pulmonary; Pyrazines; Treatment Outcome

2016
Selexipag in the treatment of pulmonary arterial hypertension: design, development, and therapy.
    Drug design, development and therapy, 2016, Volume: 10

    Topics: Acetamides; Administration, Oral; Antihypertensive Agents; Clinical Trials as Topic; Epoprostenol; Familial Primary Pulmonary Hypertension; Humans; Hypertension, Pulmonary; Pyrazines; Tachyphylaxis

2016
Use of biologics and other novel therapies for the treatment of systemic sclerosis.
    Expert review of clinical immunology, 2017, Volume: 13, Issue:5

    Topics: Abatacept; Acetamides; Antibodies, Monoclonal, Humanized; Biological Products; Clinical Trials as Topic; Fibrinolytic Agents; Fibrosis; Humans; Hypertension, Pulmonary; Indoles; Inflammation; Joints; Lisuride; Lung; PubMed; Pyrazines; Pyrazoles; Pyrimidines; Scleroderma, Systemic; Skin

2017
The year since the guidelines: a concise update on recent advances in pulmonary hypertension.
    Minerva cardioangiologica, 2017, Volume: 65, Issue:1

    Topics: Acetamides; Algorithms; Guidelines as Topic; Humans; Hypertension, Pulmonary; Phosphodiesterase Inhibitors; Pyrazines; Vasodilator Agents

2017
Selexipag: A Review in Pulmonary Arterial Hypertension.
    American journal of cardiovascular drugs : drugs, devices, and other interventions, 2017, Volume: 17, Issue:1

    Topics: Acetamides; Antihypertensive Agents; Clinical Trials as Topic; Gastrointestinal Diseases; Headache; Humans; Hypertension, Pulmonary; Pyrazines

2017
The prostacyclin pathway in pulmonary arterial hypertension: a clinical review.
    Expert review of respiratory medicine, 2017, Volume: 11, Issue:6

    Topics: Acetamides; Antihypertensive Agents; Epoprostenol; Humans; Hypertension, Pulmonary; Pyrazines; Receptors, Epoprostenol

2017
Selexipag, an Oral Prostacyclin-Receptor Agonist for Pulmonary Arterial Hypertension.
    The Annals of pharmacotherapy, 2017, Volume: 51, Issue:6

    Topics: Acetamides; Costs and Cost Analysis; Hospitalization; Humans; Hypertension, Pulmonary; Prostaglandins I; Pyrazines

2017
Clinical pharmacology, efficacy, and safety of selexipag for the treatment of pulmonary arterial hypertension.
    Expert opinion on drug safety, 2017, Volume: 16, Issue:6

    Topics: Acetamides; Acetates; Administration, Oral; Adult; Animals; Antihypertensive Agents; Drug Administration Schedule; Drug Therapy, Combination; Humans; Hypertension, Pulmonary; Pyrazines

2017
Selexipag, a selective prostacyclin receptor agonist in pulmonary arterial hypertension: a pharmacology review.
    Expert review of clinical pharmacology, 2017, Volume: 10, Issue:7

    Topics: Acetamides; Acetates; Administration, Oral; Animals; Antihypertensive Agents; Drug Design; Humans; Hypertension, Pulmonary; Pyrazines; Receptors, Epoprostenol

2017
Selexipag for the treatment of pulmonary arterial hypertension.
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2017, Aug-01, Volume: 74, Issue:15

    Topics: Acetamides; Antihypertensive Agents; Hospitalization; Humans; Hypertension, Pulmonary; Pyrazines; Randomized Controlled Trials as Topic; Treatment Outcome

2017
A Special Focus on Selexipag - Treatment of Pulmonary Arterial Hypertension.
    Current pharmaceutical design, 2017, Volume: 23, Issue:34

    Topics: Acetamides; Animals; Antihypertensive Agents; Clinical Trials as Topic; Humans; Hypertension, Pulmonary; Prodrugs; Pyrazines; Treatment Outcome

2017
Oral treprostinil in the treatment of pulmonary arterial hypertension.
    Expert opinion on pharmacotherapy, 2017, Volume: 18, Issue:15

    Topics: Acetamides; Administration, Oral; Antihypertensive Agents; Clinical Trials as Topic; Drug Approval; Epoprostenol; Humans; Hypertension, Pulmonary; Phosphodiesterase 5 Inhibitors; Pyrazines; Receptors, Prostaglandin; Treatment Outcome

2017
What Is the Role of Oral Prostacyclin Pathway Medications in Pulmonary Arterial Hypertension Management?
    Current hypertension reports, 2017, Oct-25, Volume: 19, Issue:12

    Topics: Acetamides; Antihypertensive Agents; Epoprostenol; Humans; Hypertension, Pulmonary; Pyrazines

2017
Targeted therapy in pulmonary veno-occlusive disease: time for a rethink?
    BMC pulmonary medicine, 2019, Dec-19, Volume: 19, Issue:1

    Topics: Acetamides; Adult; Anticoagulants; Antihypertensive Agents; Cardiac Catheterization; Disease Progression; Diuretics; Drug Therapy, Combination; Echocardiography, Doppler; Endothelin Receptor Antagonists; Enzyme Activators; Exercise Tolerance; Female; Humans; Male; Natriuretic Peptide, Brain; Peptide Fragments; Phosphodiesterase 5 Inhibitors; Prostaglandins; Pulmonary Arterial Hypertension; Pulmonary Diffusing Capacity; Pulmonary Edema; Pulmonary Veno-Occlusive Disease; Pyrazines; Pyrazoles; Pyrimidines; Retrospective Studies; Walk Test

2019
An evaluation of selexipag for the treatment of pulmonary hypertension.
    Expert opinion on pharmacotherapy, 2021, Volume: 22, Issue:1

    Topics: Acetamides; Administration, Oral; Adult; Antihypertensive Agents; Epoprostenol; Humans; Hypertension, Pulmonary; Pyrazines; Randomized Controlled Trials as Topic; Treatment Outcome

2021
Selexipag for the treatment of pulmonary arterial hypertension.
    Expert review of respiratory medicine, 2021, Volume: 15, Issue:5

    Topics: Acetamides; Administration, Oral; Antihypertensive Agents; Humans; Pulmonary Arterial Hypertension; Pyrazines

2021
Efficacy and safety of selexipag, an oral prostacyclin receptor agonist for the treatment of pulmonary hypertension: A meta-analysis.
    Pulmonary pharmacology & therapeutics, 2022, Volume: 72

    Topics: Acetamides; Antihypertensive Agents; Humans; Hypertension, Pulmonary; Pyrazines; Receptors, Epoprostenol

2022

Trials

31 trial(s) available for pyrazines and selexipag

ArticleYear
Selexipag: an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension.
    The European respiratory journal, 2012, Volume: 40, Issue:4

    Topics: Acetamides; Administration, Oral; Adult; Aged; Familial Primary Pulmonary Hypertension; Female; Humans; Hypertension, Pulmonary; Male; Middle Aged; Pyrazines; Receptors, Epoprostenol; Receptors, Prostaglandin; Treatment Outcome; Vascular Resistance; Vasodilator Agents

2012
Multiple-dose up-titration study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of selexipag, an orally available selective prostacyclin receptor agonist, in healthy subjects.
    Pharmacology, 2014, Volume: 94, Issue:3-4

    Topics: Acetamides; Acetates; Administration, Oral; Adult; Double-Blind Method; Healthy Volunteers; Humans; Male; Maximum Tolerated Dose; Middle Aged; Platelet Aggregation; Pyrazines; Receptors, Epoprostenol

2014
A thorough QT study in the context of an uptitration regimen with selexipag, a selective oral prostacyclin receptor agonist.
    Drug design, development and therapy, 2015, Volume: 9

    Topics: Acetamides; Administration, Oral; Adolescent; Adult; Double-Blind Method; Electrocardiography; Female; Fluoroquinolones; Humans; Long QT Syndrome; Male; Middle Aged; Moxifloxacin; Placebos; Pyrazines; Receptors, Epoprostenol; Receptors, Prostaglandin; Young Adult

2015
Pharmacokinetics and Tolerability of the Novel Oral Prostacyclin IP Receptor Agonist Selexipag.
    American journal of cardiovascular drugs : drugs, devices, and other interventions, 2015, Volume: 15, Issue:3

    Topics: Acetamides; Acetates; Administration, Oral; Adolescent; Adult; Antihypertensive Agents; Dose-Response Relationship, Drug; Double-Blind Method; Food-Drug Interactions; Half-Life; Humans; Male; Pyrazines; Receptors, Epoprostenol; Young Adult

2015
Effect of lopinavir/ritonavir on the pharmacokinetics of selexipag an oral prostacyclin receptor agonist and its active metabolite in healthy subjects.
    British journal of clinical pharmacology, 2015, Volume: 80, Issue:4

    Topics: Acetamides; Acetates; Adult; Antihypertensive Agents; Cross-Over Studies; Cytochrome P-450 CYP3A Inhibitors; Drug Combinations; Drug Interactions; Healthy Volunteers; Humans; Lopinavir; Male; Middle Aged; Pyrazines; Ritonavir; Young Adult

2015
Bioequivalence of different dose-strength tablets of selexipag, a selective prostacyclin receptor agonist, in a multiple-dose up-titration study.
    International journal of clinical pharmacology and therapeutics, 2015, Volume: 53, Issue:9

    Topics: Acetamides; Adult; Cross-Over Studies; Humans; Male; Prospective Studies; Pyrazines; Receptors, Epoprostenol; Tablets; Therapeutic Equivalency

2015
Selexipag for the Treatment of Pulmonary Arterial Hypertension.
    The New England journal of medicine, 2015, Dec-24, Volume: 373, Issue:26

    Topics: Acetamides; Aged; Disease Progression; Double-Blind Method; Drug Administration Schedule; Female; Hospitalization; Humans; Hypertension, Pulmonary; Kaplan-Meier Estimate; Male; Middle Aged; Prodrugs; Pyrazines

2015
Pharmacokinetics of the novel oral prostacyclin receptor agonist selexipag in subjects with hepatic or renal impairment.
    British journal of clinical pharmacology, 2016, Volume: 82, Issue:2

    Topics: Acetamides; Acetates; Adult; Aged; Antihypertensive Agents; Area Under Curve; Case-Control Studies; Dose-Response Relationship, Drug; Female; Humans; Kidney Diseases; Liver Diseases; Male; Middle Aged; Prospective Studies; Pyrazines; Receptors, Epoprostenol; Severity of Illness Index

2016
Investigation of Potential Pharmacodynamic and Pharmacokinetic Interactions Between Selexipag and Warfarin in Healthy Male Subjects.
    Clinical therapeutics, 2016, Volume: 38, Issue:5

    Topics: Acetamides; Acetates; Adolescent; Adult; Anticoagulants; Cross-Over Studies; Double-Blind Method; Drug Interactions; Humans; International Normalized Ratio; Male; Middle Aged; Pyrazines; Warfarin; Young Adult

2016
Absolute oral bioavailability of selexipag, a novel oral prostacyclin IP receptor agonist.
    European journal of clinical pharmacology, 2017, Volume: 73, Issue:2

    Topics: Acetamides; Acetates; Administration, Oral; Adult; Antihypertensive Agents; Biological Availability; Cross-Over Studies; Humans; Infusions, Intravenous; Male; Pyrazines; Receptors, Epoprostenol; Receptors, Prostaglandin; Young Adult

2017
Efficacy and Safety of an Orally Administered Selective Prostacyclin Receptor Agonist, Selexipag, in Japanese Patients With Pulmonary Arterial Hypertension.
    Circulation journal : official journal of the Japanese Circulation Society, 2017, Aug-25, Volume: 81, Issue:9

    Topics: Acetamides; Adult; Aged; Female; Hemodynamics; Humans; Hypertension, Pulmonary; Lung; Male; Middle Aged; Pyrazines; Receptors, Epoprostenol

2017
Population Modeling of Selexipag Pharmacokinetics and Clinical Response Parameters in Patients With Pulmonary Arterial Hypertension.
    CPT: pharmacometrics & systems pharmacology, 2017, Volume: 6, Issue:7

    Topics: Acetamides; Acetates; Adult; Antihypertensive Agents; Bilirubin; Double-Blind Method; Exercise Tolerance; Female; Humans; Hypertension, Pulmonary; Leukocyte Count; Male; Models, Biological; Natriuretic Peptide, Brain; Peptide Fragments; Pyrazines; Treatment Outcome

2017
A pharmacokinetic drug-drug interaction study between selexipag and midazolam, a CYP3A4 substrate, in healthy male subjects.
    European journal of clinical pharmacology, 2017, Volume: 73, Issue:9

    Topics: Acetamides; Adult; Antihypertensive Agents; Area Under Curve; Cross-Over Studies; Cytochrome P-450 CYP3A; Drug Interactions; Half-Life; Healthy Volunteers; Humans; Male; Midazolam; Pyrazines; Young Adult

2017
Biocomparison Study of Adult and Paediatric Dose Strengths of the Prostacyclin Receptor Agonist Selexipag.
    European journal of drug metabolism and pharmacokinetics, 2018, Volume: 43, Issue:1

    Topics: Acetamides; Acetates; Administration, Oral; Adolescent; Adult; Cross-Over Studies; Dose-Response Relationship, Drug; Healthy Volunteers; Humans; Male; Middle Aged; Pyrazines; Therapeutic Equivalency; Young Adult

2018
Effect of gemfibrozil and rifampicin on the pharmacokinetics of selexipag and its active metabolite in healthy subjects.
    British journal of clinical pharmacology, 2017, Volume: 83, Issue:12

    Topics: Acetamides; Acetates; Activation, Metabolic; Adolescent; Adult; Antihypertensive Agents; Area Under Curve; Cross-Over Studies; Cytochrome P-450 CYP2C8; Cytochrome P-450 CYP2C8 Inducers; Cytochrome P-450 CYP2C8 Inhibitors; Drug Interactions; Gemfibrozil; Germany; Half-Life; Healthy Volunteers; Humans; Male; Metabolic Clearance Rate; Middle Aged; Prodrugs; Pyrazines; Rifampin; Risk Assessment; Young Adult

2017
The metabolism and drug-drug interaction potential of the selective prostacyclin receptor agonist selexipag.
    Xenobiotica; the fate of foreign compounds in biological systems, 2018, Volume: 48, Issue:7

    Topics: Acetamides; Acetates; Drug Interactions; Enzyme Inhibitors; Esterases; Hepatocytes; Humans; Membrane Transport Proteins; Metabolic Networks and Pathways; Metabolome; Metabolomics; Microsomes, Liver; NADP; Pyrazines; Receptors, Epoprostenol; Recombinant Proteins; RNA, Messenger

2018
Selexipag for the treatment of connective tissue disease-associated pulmonary arterial hypertension.
    The European respiratory journal, 2017, Volume: 50, Issue:2

    Topics: Acetamides; Adult; Antihypertensive Agents; Disease Progression; Double-Blind Method; Female; Humans; Hypertension, Pulmonary; Lupus Erythematosus, Systemic; Male; Middle Aged; Outcome Assessment, Health Care; Pyrazines; Risk Assessment; Scleroderma, Systemic; Survival Analysis

2017
Temporary treatment interruptions with oral selexipag in pulmonary arterial hypertension: Insights from the Prostacyclin (PGI
    The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation, 2018, Volume: 37, Issue:3

    Topics: Acetamides; Administration, Oral; Antihypertensive Agents; Double-Blind Method; Female; Humans; Hypertension, Pulmonary; Male; Middle Aged; Pyrazines; Receptors, Epoprostenol; Time Factors; Withholding Treatment

2018
Efficacy and Safety of Selexipag in Adults With Raynaud's Phenomenon Secondary to Systemic Sclerosis: A Randomized, Placebo-Controlled, Phase II Study.
    Arthritis & rheumatology (Hoboken, N.J.), 2017, Volume: 69, Issue:12

    Topics: Acetamides; Adult; Antihypertensive Agents; Bayes Theorem; Double-Blind Method; Female; Humans; Male; Middle Aged; Pyrazines; Raynaud Disease; Scleroderma, Systemic; Severity of Illness Index; Treatment Outcome

2017
Targeting the Prostacyclin Pathway with Selexipag in Patients with Pulmonary Arterial Hypertension Receiving Double Combination Therapy: Insights from the Randomized Controlled GRIPHON Study.
    American journal of cardiovascular drugs : drugs, devices, and other interventions, 2018, Volume: 18, Issue:1

    Topics: Acetamides; Adult; Aged; Antihypertensive Agents; Diarrhea; Double-Blind Method; Drug Delivery Systems; Drug Therapy, Combination; Epoprostenol; Female; Headache; Humans; Hypertension, Pulmonary; Male; Middle Aged; Pyrazines; Signal Transduction

2018
[In process].
    Medizinische Monatsschrift fur Pharmazeuten, 2016, Volume: 39, Issue:8

    Topics: Acetamides; Administration, Oral; Adolescent; Adult; Aged; Double-Blind Method; Female; Humans; Hypertension, Pulmonary; Male; Middle Aged; Pyrazines; Survival Rate; Treatment Outcome; Young Adult

2016
Safety and tolerability of transition from inhaled treprostinil to oral selexipag in pulmonary arterial hypertension: Results from the TRANSIT-1 study.
    The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation, 2019, Volume: 38, Issue:1

    Topics: Acetamides; Administration, Inhalation; Administration, Oral; Antihypertensive Agents; Dose-Response Relationship, Drug; Drug Substitution; Drug Tolerance; Epoprostenol; Female; Follow-Up Studies; Humans; Male; Middle Aged; Prodrugs; Prospective Studies; Pulmonary Arterial Hypertension; Pulmonary Wedge Pressure; Pyrazines; Treatment Outcome

2019
Selexipag treatment for pulmonary arterial hypertension associated with congenital heart disease after defect correction: insights from the randomised controlled GRIPHON study.
    European journal of heart failure, 2019, Volume: 21, Issue:3

    Topics: Acetamides; Adult; Antihypertensive Agents; Cardiac Surgical Procedures; Disease Progression; Double-Blind Method; Drug Monitoring; Early Medical Intervention; Female; Heart Defects, Congenital; Humans; Hypertension, Pulmonary; Male; Middle Aged; Proportional Hazards Models; Pyrazines; Treatment Outcome

2019
Association of N-Terminal Pro Brain Natriuretic Peptide and Long-Term Outcome in Patients With Pulmonary Arterial Hypertension.
    Circulation, 2019, 05-21, Volume: 139, Issue:21

    Topics: Acetamides; Adolescent; Adult; Aged; Antihypertensive Agents; Arterial Pressure; Biomarkers; Double-Blind Method; Female; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Pulmonary Arterial Hypertension; Pulmonary Artery; Pyrazines; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; Young Adult

2019
Pharmacotherapy for pulmonary arterial hypertension.
    The Lancet. Respiratory medicine, 2020, Volume: 8, Issue:11

    Topics: Acetamides; Adult; Aged; Antihypertensive Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Male; Middle Aged; Pulmonary Arterial Hypertension; Pyrazines; Pyrimidines; Severity of Illness Index; Sulfonamides; Tadalafil; Treatment Outcome; Vascular Resistance

2020
Temporarily switching from oral to intravenous selexipag in patients with pulmonary arterial hypertension: safety, tolerability, and pharmacokinetic results from an open-label, phase III study.
    Respiratory research, 2021, Feb-03, Volume: 22, Issue:1

    Topics: Acetamides; Administration, Intravenous; Administration, Oral; Aged; Antihypertensive Agents; Cross-Over Studies; Drug Administration Routes; Female; Headache; Humans; Male; Middle Aged; Prospective Studies; Pulmonary Arterial Hypertension; Pyrazines

2021
Relationship Between Time From Diagnosis and Morbidity/Mortality in Pulmonary Arterial Hypertension: Results From the Phase III GRIPHON Study.
    Chest, 2021, Volume: 160, Issue:1

    Topics: Acetamides; Adult; Antihypertensive Agents; Disease Progression; Double-Blind Method; Female; Follow-Up Studies; Global Health; Humans; Male; Middle Aged; Morbidity; Prognosis; Pulmonary Arterial Hypertension; Pulmonary Wedge Pressure; Pyrazines; Survival Rate

2021
Three- Versus Two-Drug Therapy for Patients With Newly Diagnosed Pulmonary Arterial Hypertension.
    Journal of the American College of Cardiology, 2021, 10-05, Volume: 78, Issue:14

    Topics: Acetamides; Adult; Aged; Antihypertensive Agents; Double-Blind Method; Drug Therapy, Combination; Endothelin Receptor Antagonists; Female; Humans; Male; Middle Aged; Phosphodiesterase 5 Inhibitors; Pulmonary Arterial Hypertension; Pyrazines; Pyrimidines; Sulfonamides; Tadalafil

2021
Long-Term Survival, Safety and Tolerability with Selexipag in Patients with Pulmonary Arterial Hypertension: Results from GRIPHON and its Open-Label Extension.
    Advances in therapy, 2022, Volume: 39, Issue:1

    Topics: Acetamides; Antihypertensive Agents; Humans; Hypertension, Pulmonary; Pulmonary Arterial Hypertension; Pyrazines

2022
The impact of comorbidities on selexipag treatment effect in patients with pulmonary arterial hypertension: insights from the GRIPHON study.
    European journal of heart failure, 2022, Volume: 24, Issue:1

    Topics: Acetamides; Antihypertensive Agents; Comorbidity; Double-Blind Method; Heart Failure; Humans; Hypertension, Pulmonary; Pulmonary Arterial Hypertension; Pyrazines

2022
Selexipag for the treatment of chronic thromboembolic pulmonary hypertension.
    The European respiratory journal, 2022, Volume: 60, Issue:1

    Topics: Acetamides; Antihypertensive Agents; Chronic Disease; Dyspnea; Humans; Hypertension, Pulmonary; Pulmonary Embolism; Pyrazines; Treatment Outcome

2022

Other Studies

68 other study(ies) available for pyrazines and selexipag

ArticleYear
2-[4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy]-N-(methylsulfonyl)acetamide (NS-304), an orally available and long-acting prostacyclin receptor agonist prodrug.
    The Journal of pharmacology and experimental therapeutics, 2007, Volume: 322, Issue:3

    Topics: Acetamides; Administration, Oral; Animals; Dogs; Femur; Half-Life; Humans; Male; Prodrugs; Pyrazines; Rats; Receptors, Epoprostenol; Regional Blood Flow; Vascular Diseases; Vasodilation

2007
Synthesis and evaluation of N-acylsulfonamide and N-acylsulfonylurea prodrugs of a prostacyclin receptor agonist.
    Bioorganic & medicinal chemistry, 2007, Dec-15, Volume: 15, Issue:24

    Topics: Acetamides; Animals; Dogs; Drug Evaluation, Preclinical; Epoprostenol; Haplorhini; Humans; Male; Microsomes; Molecular Structure; Platelet Aggregation Inhibitors; Prodrugs; Pyrazines; Rats; Rats, Sprague-Dawley; Receptors, Epoprostenol; Sulfonylurea Compounds

2007
A long-acting and highly selective prostacyclin receptor agonist prodrug, 2-{4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-N-(methylsulfonyl)acetamide (NS-304), ameliorates rat pulmonary hypertension with unique relaxant responses of its active fo
    The Journal of pharmacology and experimental therapeutics, 2008, Volume: 326, Issue:3

    Topics: Acetamides; Acetates; Animals; Antihypertensive Agents; CHO Cells; Cricetinae; Cricetulus; Dose-Response Relationship, Drug; Humans; Hypertension, Pulmonary; In Vitro Techniques; Male; Prodrugs; Pulmonary Artery; Pyrazines; Rats; Rats, Sprague-Dawley; Receptors, Epoprostenol; Vasodilation

2008
Selexipag: a selective prostacyclin receptor agonist that does not affect rat gastric function.
    The Journal of pharmacology and experimental therapeutics, 2010, Volume: 335, Issue:1

    Topics: Acetamides; Animals; Dinoprostone; Dose-Response Relationship, Drug; Epoprostenol; Gastric Emptying; Gastrointestinal Transit; Humans; Iloprost; Male; Muscle Contraction; Pulmonary Artery; Pyrazines; Rats; Receptors, Epoprostenol; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Stomach

2010
Differential effects of Selexipag [corrected] and prostacyclin analogs in rat pulmonary artery.
    The Journal of pharmacology and experimental therapeutics, 2012, Volume: 343, Issue:3

    Topics: Acetamides; Acetates; Alprostadil; Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Epoprostenol; Hypertension, Pulmonary; In Vitro Techniques; Male; Pulmonary Artery; Pyrazines; Rats; Rats, Wistar; Receptors, Epoprostenol; Vasoconstrictor Agents; Vasodilation; Vasodilator Agents

2012
[Pulmonary hypertension].
    Deutsche medizinische Wochenschrift (1946), 2012, Volume: 137, Issue:40

    Topics: Acetamides; Administration, Oral; Antihypertensive Agents; Benzamides; Drug Therapy, Combination; Early Medical Intervention; Epoprostenol; Humans; Hypertension, Pulmonary; Imatinib Mesylate; Piperazines; Pyrazines; Pyrazoles; Pyrimidines; Randomized Controlled Trials as Topic; Sulfonamides

2012
Differential actions of the prostacyclin analogues treprostinil and iloprost and the selexipag metabolite, MRE-269 (ACT-333679) in rat small pulmonary arteries and veins.
    Prostaglandins & other lipid mediators, 2013, Volume: 106

    Topics: Acetamides; Acetates; Animals; Benzofurans; Benzyl Compounds; Epoprostenol; Female; Iloprost; Imidazoles; Male; Propionates; Pulmonary Artery; Pulmonary Veins; Pyrazines; Rats; Rats, Sprague-Dawley; Receptors, Epoprostenol; Vasodilation

2013
Selexipag: An Oral and Selective IP Prostacyclin Receptor Agonist for the Treatment of Pulmonary Arterial Hypertension.
    Journal of medicinal chemistry, 2015, Sep-24, Volume: 58, Issue:18

    Topics: Acetamides; Acetates; Administration, Oral; Animals; CHO Cells; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cricetulus; Dogs; Double-Blind Method; Haplorhini; Humans; Hypertension, Pulmonary; Myocytes, Smooth Muscle; Platelet Aggregation Inhibitors; Pulmonary Artery; Pyrazines; Randomized Controlled Trials as Topic; Rats; Receptors, Epoprostenol; Structure-Activity Relationship

2015
Selexipag for the treatment of pulmonary arterial hypertension.
    Expert review of respiratory medicine, 2016, Volume: 10, Issue:1

    Topics: Acetamides; Antihypertensive Agents; Humans; Hypertension, Pulmonary; Pyrazines

2016
Selexipag (Uptravi) for pulmonary arterial hypertension.
    The Medical letter on drugs and therapeutics, 2016, Feb-15, Volume: 58, Issue:1488

    Topics: Acetamides; Administration, Oral; Antihypertensive Agents; Drug Interactions; Humans; Hypertension, Pulmonary; Pyrazines; Randomized Controlled Trials as Topic; Receptors, Epoprostenol; Receptors, Prostaglandin; Tablets; Treatment Outcome

2016
Prostaglandin I2 Receptor Agonism Preserves β-Cell Function and Attenuates Albuminuria Through Nephrin-Dependent Mechanisms.
    Diabetes, 2016, Volume: 65, Issue:5

    Topics: Acetamides; Acetates; Animals; Cell Line; Cell Survival; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Insulin-Secreting Cells; Membrane Proteins; Mice, Inbred C57BL; Mice, Knockout; Mutation; Phosphorylation; Podocytes; Prodrugs; Protein Processing, Post-Translational; Pyrazines; Receptors, Epoprostenol; Renal Insufficiency; RNA Interference

2016
A comparison of vasodilation mode among selexipag (NS-304; [2-{4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-N-(methylsulfonyl)acetamide]), its active metabolite MRE-269 and various prostacyclin receptor agonists in rat, porcine and human pulmonar
    European journal of pharmacology, 2017, Jan-15, Volume: 795

    Topics: Acetamides; Acetates; Animals; Cyclic AMP; Endothelium, Vascular; Humans; Male; Nitric Oxide; Pulmonary Artery; Pyrazines; Rats; Receptors, Epoprostenol; Swine; Vasodilation; Vasodilator Agents

2017
Pharmacokinetics of the selective prostacyclin receptor agonist selexipag in rats, dogs and monkeys.
    Xenobiotica; the fate of foreign compounds in biological systems, 2018, Volume: 48, Issue:2

    Topics: Acetamides; Animals; Antihypertensive Agents; Dogs; Intestinal Absorption; Macaca fascicularis; Pyrazines; Rats; Receptors, Epoprostenol; Species Specificity; Tissue Distribution

2018
Selexipag Active Metabolite ACT-333679 Displays Strong Anticontractile and Antiremodeling Effects but Low
    The Journal of pharmacology and experimental therapeutics, 2017, Volume: 362, Issue:1

    Topics: Acetamides; Acetates; Animals; beta-Arrestins; Cell Proliferation; CHO Cells; Contractile Proteins; Cricetinae; Cricetulus; Cyclic AMP; Epoprostenol; Extracellular Matrix; Humans; Hypertension, Pulmonary; Iloprost; Male; Muscle Contraction; Muscle Relaxation; Pyrazines; Rats; Rats, Inbred SHR; Rats, Wistar; Receptors, Epoprostenol

2017
Transition of Intravenous Treprostinil to Oral Therapy in a Patient with Functional Class IV Chronic Thromboembolic Pulmonary Hypertension.
    Pharmacotherapy, 2017, Volume: 37, Issue:8

    Topics: Acetamides; Administration, Oral; Adult; Antihypertensive Agents; Chronic Disease; Epoprostenol; Humans; Hypertension, Pulmonary; Infusions, Intravenous; Male; Paraplegia; Pyrazines; Severity of Illness Index; Ventricular Dysfunction, Right

2017
Single-Center Experience Using Selexipag in a Pediatric Population.
    Pediatric cardiology, 2017, Volume: 38, Issue:7

    Topics: Acetamides; Adolescent; Antihypertensive Agents; Child; Epoprostenol; Female; Heart Defects, Congenital; Humans; Hypertension, Pulmonary; Male; Pyrazines; Treatment Outcome; Walk Test; Young Adult

2017
Future Applications of the Selective Prostacyclin (IP) Receptor Agonist Selexipag in Pediatric Pulmonary Hypertension.
    Pediatric cardiology, 2017, Volume: 38, Issue:7

    Topics: Acetamides; Child; Epoprostenol; Humans; Hypertension, Pulmonary; Pyrazines

2017
Editorial: Clinical Trials in Raynaud's Phenomenon: A Spoonful of Sugar (Pill) Makes the Medicine Go Down (in Flames).
    Arthritis & rheumatology (Hoboken, N.J.), 2017, Volume: 69, Issue:12

    Topics: Acetamides; Adult; Humans; Pyrazines; Raynaud Disease; Scleroderma, Systemic; Sugars

2017
New Drugs 2017, part 3.
    Nursing, 2017, Volume: 47, Issue:11

    Topics: Acetamides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antitoxins; Bridged Bicyclo Compounds, Heterocyclic; Carbazoles; Chenodeoxycholic Acid; Drug Approval; Humans; Indoles; Morpholinos; Oligonucleotides; Piperidines; Polydeoxyribonucleotides; Pyrazines; Sulfonamides; United States; United States Food and Drug Administration

2017
Successful transition from Treprostinil to Selexipag in patient with severe pulmonary arterial hypertension.
    BMC pulmonary medicine, 2017, Oct-26, Volume: 17, Issue:1

    Topics: Acetamides; Adult; Antihypertensive Agents; Drug Therapy, Combination; Epoprostenol; Exercise Tolerance; Familial Primary Pulmonary Hypertension; Female; Hemodynamics; Humans; Prospective Studies; Pyrazines; Pyrimidines; Sulfonamides

2017
Cross-species comparison of the metabolism and excretion of selexipag.
    Xenobiotica; the fate of foreign compounds in biological systems, 2019, Volume: 49, Issue:3

    Topics: Acetamides; Acetates; Animals; Bile; Body Fluids; Chromatography, High Pressure Liquid; Dogs; Hepatocytes; Macaca fascicularis; Metabolome; Microsomes, Liver; Pyrazines; Rats; Rats, Sprague-Dawley; Species Specificity

2019
Reply.
    Arthritis & rheumatology (Hoboken, N.J.), 2018, Volume: 70, Issue:6

    Topics: Acetamides; Adult; Humans; Pyrazines; Raynaud Disease; Scleroderma, Systemic

2018
Patient Perceptions of the Raynaud's Condition Score Diary Provide Insight Into Its Performance in Clinical Trials of Raynaud's Phenomenon: Comment on the Article by Denton et al.
    Arthritis & rheumatology (Hoboken, N.J.), 2018, Volume: 70, Issue:6

    Topics: Acetamides; Adult; Humans; Pyrazines; Raynaud Disease; Scleroderma, Systemic

2018
Safety concerns regarding selexipag in pulmonary arterial hypertension.
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2018, 04-01, Volume: 75, Issue:7

    Topics: Acetamides; Antihypertensive Agents; Familial Primary Pulmonary Hypertension; Humans; Hypertension, Pulmonary; Pyrazines

2018
Safety concerns regarding selexipag in pulmonary arterial hypertension.
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2018, 04-01, Volume: 75, Issue:7

    Topics: Acetamides; Antihypertensive Agents; Humans; Hypertension, Pulmonary; Pyrazines; Risk Evaluation and Mitigation

2018
Selective Prostacyclin Receptor Agonist Selexipag, in Contrast to Prostacyclin Analogs, Does Not Evoke Paradoxical Vasoconstriction of the Rat Femoral Artery.
    The Journal of pharmacology and experimental therapeutics, 2018, Volume: 365, Issue:3

    Topics: Acetamides; Animals; Epoprostenol; Femoral Artery; Male; Pyrazines; Rats; Rats, Wistar; Receptors, Epoprostenol; Receptors, Prostaglandin E, EP3 Subtype; Vasoconstriction

2018
Effects of selexipag and its active metabolite in contrasting the profibrotic myofibroblast activity in cultured scleroderma skin fibroblasts.
    Arthritis research & therapy, 2018, 05-02, Volume: 20, Issue:1

    Topics: Acetamides; Acetates; Actins; Aged; Cells, Cultured; Female; Fibroblasts; Gene Expression; Humans; Middle Aged; Muscle, Smooth; Myofibroblasts; Pyrazines; S100 Calcium-Binding Protein A4; Scleroderma, Systemic; Skin

2018
Treatment of rat congenital diaphragmatic hernia with sildenafil and NS-304, selexipag's active compound, at the pseudoglandular stage improves lung vasculature.
    American journal of physiology. Lung cellular and molecular physiology, 2018, 08-01, Volume: 315, Issue:2

    Topics: Acetamides; Animals; Drug Therapy, Combination; Hernias, Diaphragmatic, Congenital; Humans; Lung; Pyrazines; Rats; Rats, Sprague-Dawley; Sildenafil Citrate

2018
Living With Severe Pulmonary Arterial Hypertension Without an Infusion Pump? Selexipag has a Role to Play.
    Archivos de bronconeumologia, 2019, Volume: 55, Issue:2

    Topics: Acetamides; Antihypertensive Agents; Drug Substitution; Drug Therapy, Combination; Epoprostenol; Female; Humans; Infusion Pumps; Middle Aged; Phenylpropionates; Pulmonary Arterial Hypertension; Pyrazines; Pyridazines; Sildenafil Citrate; Tadalafil; Vasodilator Agents

2019
Contribution of Human Liver and Intestinal Carboxylesterases to the Hydrolysis of Selexipag In Vitro.
    Journal of pharmaceutical sciences, 2019, Volume: 108, Issue:2

    Topics: Acetamides; Antihypertensive Agents; Carboxylesterase; Carboxylic Ester Hydrolases; Humans; Hydrolysis; Intestinal Mucosa; Intestines; Kinetics; Liver; Pyrazines

2019
Transition from treprostinil to selexipag in patients with pulmonary arterial hypertension: Case series.
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2018, Dec-01, Volume: 75, Issue:23

    Topics: Acetamides; Administration, Intravenous; Administration, Oral; Adult; Antihypertensive Agents; Drug Substitution; Epoprostenol; Female; Humans; Hypertension, Pulmonary; Injections, Subcutaneous; Male; Middle Aged; Pyrazines

2018
Determining the value contribution of selexipag for the treatment of pulmonary arterial hypertension (PAH) in Spain using reflective multi-criteria decision analysis (MCDA).
    Orphanet journal of rare diseases, 2018, 12-10, Volume: 13, Issue:1

    Topics: Acetamides; Decision Making; Decision Support Techniques; Humans; Hypertension, Pulmonary; Pyrazines; Quality of Life; Rare Diseases; Spain

2018
Use of an implantable wireless pulmonary pressure monitor during transition of therapy in pulmonary arterial hypertension.
    The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation, 2019, Volume: 38, Issue:2

    Topics: Acetamides; Antihypertensive Agents; Drug Substitution; Epoprostenol; Equipment Design; Female; Humans; Middle Aged; Monitoring, Physiologic; Prodrugs; Pulmonary Arterial Hypertension; Pulmonary Artery; Pulmonary Wedge Pressure; Pyrazines; Remote Sensing Technology

2019
Right Heart Catheterization Further Confirms Successful Transition from Parenteral Prostanoid to Oral Selexipag.
    Archivos de bronconeumologia, 2019, Volume: 55, Issue:7

    Topics: Acetamides; Administration, Oral; Cardiac Catheterization; Drug Substitution; Epoprostenol; Female; Follow-Up Studies; Humans; Hypertension, Pulmonary; Injections, Subcutaneous; Pyrazines

2019
Real-Life Experience with Selexipag as an Add-On Therapy to Oral Combination Therapy in Patients with Pulmonary Arterial or Distal Chronic Thromboembolic Pulmonary Hypertension: A Retrospective Analysis.
    Lung, 2019, Volume: 197, Issue:3

    Topics: Acetamides; Aged; Antihypertensive Agents; Chronic Disease; Cohort Studies; Drug Therapy, Combination; Echocardiography; Endothelin Receptor Antagonists; Enzyme Activators; Exercise Test; Female; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Oxygen Consumption; Peptide Fragments; Phosphodiesterase 5 Inhibitors; Pulmonary Arterial Hypertension; Pulmonary Embolism; Pyrazines; Quality of Life; Retrospective Studies; Soluble Guanylyl Cyclase; Tricuspid Valve; Walk Test

2019
Transition from intravenous treprostinil to enteral selexipag in an infant with pulmonary arterial hypertension.
    Cardiology in the young, 2019, Volume: 29, Issue:6

    Topics: Acetamides; Administration, Intravenous; Administration, Oral; Antihypertensive Agents; Echocardiography; Enteral Nutrition; Epoprostenol; Humans; Infant, Newborn; Infusions, Intravenous; Male; Pulmonary Arterial Hypertension; Pulmonary Wedge Pressure; Pyrazines; Receptors, Prostaglandin

2019
Thyroid Dysfunction in Patients with Pulmonary Artery Hypertension (PAH): The Effect of Therapies Affecting the Prostanoid Pathway.
    Lung, 2019, Volume: 197, Issue:6

    Topics: Acetamides; Adult; Aged; Antihypertensive Agents; Epoprostenol; Female; Goiter; Graves Disease; Hashimoto Disease; Humans; Hyperthyroidism; Male; Pulmonary Arterial Hypertension; Pyrazines; Thyroiditis, Autoimmune; Thyrotoxicosis

2019
Experience in Transitioning From Parenteral Prostacyclins to Selexipag in Pulmonary Arterial Hypertension.
    Journal of cardiovascular pharmacology, 2020, Volume: 75, Issue:4

    Topics: Acetamides; Antihypertensive Agents; Arterial Pressure; Drug Substitution; Feasibility Studies; Female; Humans; Infusions, Parenteral; Male; Middle Aged; Prospective Studies; Prostaglandins I; Pulmonary Arterial Hypertension; Pulmonary Artery; Pyrazines; Receptors, Epoprostenol; Time Factors; Treatment Outcome

2020
Transition from intravenous epoprostenol to selexipag in pulmonary arterial hypertension: a word of caution.
    The European respiratory journal, 2020, Volume: 55, Issue:6

    Topics: Acetamides; Antihypertensive Agents; Epoprostenol; Humans; Pulmonary Arterial Hypertension; Pyrazines

2020
NTP42, a novel antagonist of the thromboxane receptor, attenuates experimentally induced pulmonary arterial hypertension.
    BMC pulmonary medicine, 2020, Apr-06, Volume: 20, Issue:1

    Topics: Acetamides; Animals; Antihypertensive Agents; Disease Models, Animal; Heart Ventricles; Hemodynamics; Humans; Hypertrophy, Right Ventricular; Male; Monocrotaline; Pulmonary Arterial Hypertension; Pulmonary Artery; Pyrazines; Rats; Rats, Inbred WKY; Receptors, Thromboxane; Sildenafil Citrate; Vascular Remodeling

2020
Selexipag Use in Clinical Practice: Mind the Gap.
    Chest, 2020, Volume: 157, Issue:4

    Topics: Acetamides; Consensus; Epoprostenol; Humans; Prostaglandins I; Pulmonary Arterial Hypertension; Pyrazines

2020
Selexipag for the treatment of children with pulmonary arterial hypertension: First multicenter experience in drug safety and efficacy.
    The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation, 2020, Volume: 39, Issue:7

    Topics: Acetamides; Administration, Oral; Antihypertensive Agents; Blood Pressure; Child; Female; Humans; Male; Prodrugs; Prospective Studies; Pulmonary Arterial Hypertension; Pulmonary Artery; Pyrazines; Treatment Outcome

2020
[Experience with Selexipag to Treat Pulmonary Arterial Hypertension].
    Kardiologiia, 2020, Mar-30, Volume: 60, Issue:4

    Topics: Acetamides; Humans; Pulmonary Arterial Hypertension; Pyrazines

2020
Clopidogrel, a CYP2C8 inhibitor, causes a clinically relevant increase in the systemic exposure to the active metabolite of selexipag in healthy subjects.
    British journal of clinical pharmacology, 2021, Volume: 87, Issue:1

    Topics: Acetamides; Clopidogrel; Cytochrome P-450 CYP2C8; Drug Interactions; Healthy Volunteers; Humans; Male; Pyrazines

2021
Use of selexipag in a child with pulmonary hypertension associated with sickle cell disease.
    The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation, 2020, Volume: 39, Issue:9

    Topics: Acetamides; Anemia, Sickle Cell; Antihypertensive Agents; Child; Female; Humans; Hypertension, Pulmonary; Prodrugs; Pulmonary Wedge Pressure; Pyrazines

2020
Rosacea induced by selexipag in a patient with pulmonary arterial hypertension.
    Dermatologic therapy, 2020, Volume: 33, Issue:6

    Topics: Acetamides; Antihypertensive Agents; Humans; Pulmonary Arterial Hypertension; Pyrazines; Rosacea

2020
Rapid transition from oral selexipag to parenteral treprostinil in a patient with mixed-etiology pulmonary hypertension.
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2020, 07-23, Volume: 77, Issue:15

    Topics: Acetamides; Administration, Intravenous; Administration, Oral; Aged; Antihypertensive Agents; Blood Pressure; Drug Substitution; Epoprostenol; Female; Humans; Hypertension, Pulmonary; Injections, Subcutaneous; Pyrazines; Time Factors

2020
Novel Documentation of Onset and Rapid Advancement of Pulmonary Arterial Hypertension without Symptoms in BMPR2 Mutation Carriers: Cautionary Tales?
    American journal of respiratory and critical care medicine, 2020, 12-01, Volume: 202, Issue:11

    Topics: Acetamides; Adolescent; Antihypertensive Agents; Asymptomatic Diseases; Bone Morphogenetic Protein Receptors, Type II; Cardiac Catheterization; Disease Progression; Dyspnea; Echocardiography; Exercise Tolerance; Female; Genetic Testing; Heterozygote; Humans; Male; Phenylpropionates; Pulmonary Arterial Hypertension; Pyrazines; Pyridazines; Sildenafil Citrate; Syncope; Vasodilator Agents

2020
Simultaneous quantification and pharmacokinetic investigation of selexipag and its main metabolite ACT-333679 in rat plasma by UPLC-MS/MS method.
    Journal of pharmaceutical and biomedical analysis, 2020, Oct-25, Volume: 190

    Topics: Acetamides; Acetates; Animals; Chromatography, High Pressure Liquid; Chromatography, Liquid; Pyrazines; Rats; Rats, Sprague-Dawley; Reproducibility of Results; Tandem Mass Spectrometry

2020
Potential of Selexipag in Chronic Thromboembolic Pulmonary Hypertension Medical Therapy.
    Circulation journal : official journal of the Japanese Circulation Society, 2020, 09-25, Volume: 84, Issue:10

    Topics: Acetamides; Double-Blind Method; Humans; Hypertension, Pulmonary; Japan; Pyrazines

2020
A Case Report of a Patient With Pulmonary Arterial Hypertension Transitioned From Inhaled Iloprost to Selexipag.
    Journal of pharmacy practice, 2021, Volume: 34, Issue:6

    Topics: Acetamides; Antihypertensive Agents; Female; Humans; Hypertension, Pulmonary; Iloprost; Middle Aged; Pulmonary Arterial Hypertension; Pyrazines

2021
Clinical evaluation of drug-drug interactions between the cytochrome P450 substrates selexipag and clopidogrel in Japanese volunteers.
    British journal of clinical pharmacology, 2021, Volume: 87, Issue:4

    Topics: Acetamides; Area Under Curve; Clopidogrel; Cross-Over Studies; Cytochrome P-450 CYP2C8; Cytochrome P-450 Enzyme System; Drug Interactions; Healthy Volunteers; Humans; Japan; Pharmaceutical Preparations; Pyrazines

2021
The selective PGI2 receptor agonist selexipag ameliorates Sugen 5416/hypoxia-induced pulmonary arterial hypertension in rats.
    PloS one, 2020, Volume: 15, Issue:10

    Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Acetamides; Animals; Cell Proliferation; Collagen Type I; Disease Models, Animal; Heart Ventricles; Hemodynamics; Hypertrophy, Right Ventricular; Hypoxia; Indoles; Lung; Male; Pulmonary Arterial Hypertension; Pyrazines; Pyrroles; Rats, Sprague-Dawley; Receptors, Epoprostenol; Systole; Vascular Remodeling

2020
Prostaglandin I2 (PGI
    Developmental and comparative immunology, 2021, Volume: 115

    Topics: Acetamides; Animals; Brucella abortus; Brucellosis; Cyclooxygenase 2; Cytochrome P-450 Enzyme System; Epoprostenol; Female; Humans; Macrophages; Mice; Pyrazines; RAW 264.7 Cells; Receptors, Epoprostenol; Signal Transduction; Specific Pathogen-Free Organisms

2021
Patient and disease characteristics of the first 500 patients with pulmonary arterial hypertension treated with selexipag in real-world settings from SPHERE.
    The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation, 2021, Volume: 40, Issue:4

    Topics: Acetamides; Aged; Antihypertensive Agents; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Incidence; Male; Middle Aged; Prospective Studies; Pulmonary Arterial Hypertension; Pulmonary Wedge Pressure; Pyrazines; Receptors, Prostaglandin; Treatment Outcome; United States

2021
Use of the Prostacyclin Receptor Agonist Selexipag in Patients With Pulmonary Arterial Hypertension Associated With Eisenmenger Syndrome.
    The Canadian journal of cardiology, 2021, Volume: 37, Issue:8

    Topics: Acetamides; Adult; Antihypertensive Agents; Eisenmenger Complex; Female; Humans; Middle Aged; Pulmonary Arterial Hypertension; Pyrazines; Receptors, Epoprostenol

2021
Selexipag use for paediatric pulmonary hypertension: a single centre report focussed on congenital heart disease patients.
    Cardiology in the young, 2021, Volume: 31, Issue:9

    Topics: Acetamides; Adult; Antihypertensive Agents; Child; Heart Defects, Congenital; Humans; Hypertension, Pulmonary; Pyrazines

2021
Development of an efficient stability-indicating LC-MS/MS method for the analysis of selexipag and characterization of its degradation products.
    Biomedical chromatography : BMC, 2021, Volume: 35, Issue:10

    Topics: Acetamides; Chromatography, High Pressure Liquid; Drug Contamination; Linear Models; Pyrazines; Reproducibility of Results; Sensitivity and Specificity; Tandem Mass Spectrometry

2021
Selexipag Therapy for Raynaud Phenomenon-induced Severe Digital Ischemia in Intravenous Epoprostenol Responders With Connective Tissue Disease.
    The Journal of rheumatology, 2021, Volume: 48, Issue:4

    Topics: Acetamides; Antihypertensive Agents; Connective Tissue Diseases; Epoprostenol; Humans; Ischemia; Pyrazines; Raynaud Disease

2021
[Triple combination therapy with macitentan, riociguat, and selexipag in a patient with idiopathic pulmonary arterial hypertension (functional class III)].
    Kardiologiia, 2021, Oct-30, Volume: 61, Issue:10

    Topics: Acetamides; Antihypertensive Agents; Familial Primary Pulmonary Hypertension; Female; Humans; Pyrazines; Pyrazoles; Pyrimidines; Sulfonamides

2021
Selexipag and the pulmonary hypertension continuum.
    European journal of heart failure, 2022, Volume: 24, Issue:1

    Topics: Acetamides; Heart Failure; Humans; Hypertension, Pulmonary; Pyrazines

2022
Effect of quercetin on the pharmacokinetics of selexipag and its active metabolite in beagles.
    Pharmaceutical biology, 2022, Volume: 60, Issue:1

    Topics: Acetamides; Acetates; Animals; Antihypertensive Agents; Area Under Curve; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP2C8 Inhibitors; Dogs; Female; Herb-Drug Interactions; Male; Pyrazines; Quercetin; Tandem Mass Spectrometry

2022
Successful transition from intravenous epoprostenol to oral selexipag and inhaled iloprost in a case of severe pulmonary arterial hypertension associated with systemic lupus erythematosus.
    Modern rheumatology case reports, 2022, 06-24, Volume: 6, Issue:2

    Topics: Acetamides; Adult; Epoprostenol; Female; Humans; Hypertension, Pulmonary; Iloprost; Lupus Erythematosus, Systemic; Pulmonary Arterial Hypertension; Pyrazines; Quality of Life

2022
Selexipag Improves Lipopolysaccharide-Induced ARDS on C57BL/6 Mice by Modulating the cAMP/PKA and cAMP/Epac1 Signaling Pathways.
    Biological & pharmaceutical bulletin, 2022, Aug-01, Volume: 45, Issue:8

    Topics: Acetamides; Animals; Inflammation; Lipopolysaccharides; Lung; Mice; Mice, Inbred C57BL; Pyrazines; Respiratory Distress Syndrome; Signal Transduction

2022
Selexipag for inoperable CTEPH: why meeting a primary endpoint simply isn't enough.
    The European respiratory journal, 2022, Volume: 60, Issue:1

    Topics: Acetamides; Humans; Hypertension, Pulmonary; Pyrazines

2022
Case report: apatinib plus selexipag as a novel therapy for pulmonary tumor thrombotic microangiopathy accompanied by pulmonary hypertension associated with gastric carcinoma.
    Medicine, 2022, Jul-15, Volume: 101, Issue:28

    Topics: Acetamides; Drug Therapy, Combination; Female; Humans; Hypertension, Pulmonary; Lung Neoplasms; Middle Aged; Pulmonary Artery; Pyrazines; Pyridines; Receptors, Epoprostenol; Receptors, Vascular Endothelial Growth Factor; Stomach Neoplasms; Thrombotic Microangiopathies

2022
Validation of the new paediatric pulmonary hypertension risk score by CMR and speckle tracking echocardiography.
    European journal of clinical investigation, 2022, Volume: 52, Issue:11

    Topics: Acetamides; Child; Echocardiography; Humans; Hypertension, Pulmonary; Magnetic Resonance Imaging; Pyrazines; Risk Factors; Young Adult

2022
Effectiveness and persistence with selexipag in pulmonary arterial hypertension in the real-life setting.
    European journal of internal medicine, 2023, Volume: 111

    Topics: Acetamides; Antihypertensive Agents; Humans; Hypertension, Pulmonary; Pulmonary Arterial Hypertension; Pyrazines

2023